Clinical trial
The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
NCT06707532
Study timeline
Study start (actual)2024-08-01Date precision: day
Registry last updated2024-11-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Kidney Failure, Acuteunresolved
Myopathy; Drugsunresolved
Heart Arrhythmiaunresolved
Succinylcholine Sensitivityunresolved
Muscle Relaxationunresolved
General Anesthetic Drug Adverse Reactionunresolved
Projectionunresolved
Interventions
PropofolDRUG · verified · RxNorm: propofol
RocuroniumDRUG · verified · RxNorm: rocuronium
Sponsors & collaborators
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06707532 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.